NSE · GLAND
Gland Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,402 Cr with net profit ₹425 Cr — a 30.31% net margin, versus 28.32% the period before.
Shareholding
As of 2026-09-30
- Promoter45.75%
- Public10.67%
- FII10.36%
- DII33.21%
1,25,667 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.14× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 6.01 percentage points to 45.75% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #2 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited(this company) | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
AI analysis
AI-generated · google/gemini-2.5-flashGland Pharma Limited is listed on the Indian markets with a market capitalization of Rs 40565 Cr. The company reported revenue of Rs 5830.11 Cr and an EPS of Rs 63.29. Its debt-to-equity ratio is 0.04.
Positives
- +The company has a low debt-to-equity ratio of 0.04.
- +Promoter holding is stable at 51.7665% as of June 30, 2026.
- +The company has not reported any promoter share pledges.
Negatives
- −Revenue growth for the last year was -0.8%, indicating a contraction in revenue.
- −The trailing twelve-month P/E ratio is high at 110.47.
- −The Return on Equity (ROE) is 9.92%, which is below 10%.
Financial Performance
Gland Pharma Limited's revenue for the last year was Rs 5830.11 Cr, marking a growth of -0.8%. The company's profit margin stood at 15.98%. Over the past year, the company's EPS was Rs 63.29. The latest annual net profit recorded was Rs 698.526 Cr in Mar 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 9.92% and Return on Capital Employed (ROCE) is 14.02%. The profit margin for Gland Pharma Limited is 15.98%. The trailing twelve-month EPS is Rs 63.29.
Balance Sheet
Gland Pharma Limited has a book value of Rs 627.91 per share. The debt-to-equity ratio is low at 0.04, indicating a limited reliance on debt financing. The company has no reported promoter share pledges.
Ownership & Pledges
As of June 30, 2026, promoters held 51.7665% of the shares. DIIs held 30.4428%, FIIs held 8.74%, and the public held 9.0507%. The total number of shareholders was 108266. There are no reported promoter share pledges.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.